Nearly 900 rats, each genetically distinct, taught UC San Diego researchers something unexpected: the key to cocaine addiction might not lie in the brain alone, but in the liver.
In a sweeping genetic study published in Nature Communications, researchers tracked how individual differences in drug metabolism shape whether an animal develops compulsive cocaine-seeking behavior. The finding marks a fundamental shift in how scientists think about addiction vulnerability—and where they might look for treatments.
"Finding a liver-based enzyme that shapes cocaine-taking behavior was a real 'aha' moment for us," said Olivier George, a professor of psychiatry at UC San Diego School of Medicine, whose lab conducted the behavioral studies underpinning the work. "It reminds us that addiction isn't only in the brain. It's a complex puzzle involving how the entire body processes the drug."
The study centered on a specific group of genes called Ces1, which produce enzymes responsible for breaking down cocaine in the body. Researchers analyzed millions of genetic markers across their rat cohort and identified six major genetic regions linked to addiction-like behaviors—including how quickly animals escalated their drug intake and the intervals between doses. Crucially, variations in Ces1 genes correlated strongly with how frequently and compulsively the rats self-administered cocaine.
This wasn't pure serendipity. The team deliberately chose heterogeneous stock rats, a model system that mirrors the vast genetic diversity found in human populations. That diversity proved essential. By comparing animals genetically susceptible to addiction with those naturally resistant, the researchers could isolate the biological factors that tip the scales toward dependency.
Abraham Palmer, a professor of psychiatry who led the genetic modeling, described the significance plainly: "Identifying those genes is an important goal, because drugs could then be developed to target those genes, shifting genetically susceptible people to become more like genetically resistant people."
Current addiction research typically focuses on the brain's reward systems and neural pathways. The UC San Diego team's work suggests that cocaine metabolism—how the body chemically dismantles the drug—may be equally important in determining who becomes addicted. If scientists can alter how the liver processes cocaine, they might be able to reduce its addictive impact before it ever reaches the brain.
The research also cleared a critical bridge between animal studies and human medicine. The team replicated a genetic link (Trak2) previously identified in humans, providing evidence that the biological mechanisms they discovered in rats might translate to real human vulnerability. "Seeing the Ces1 signal validate a hypothesis that has been circulating for decades is incredibly exciting," said Montana Kay Lara, a postdoctoral researcher who helped connect the study's behavioral and genetic threads. "It gives us a concrete target to test whether changing how cocaine is metabolized can blunt the drive toward compulsive use."
Palmer credits the breakthrough to a decade of sustained collaboration across multiple laboratories and federal partners—work that no single lab could have accomplished alone. The team now moves into the next phase: understanding exactly how genetic mutations alter enzyme function, and mining their extensive Preclinical Addiction Biobanks—collections of blood, urine, brain, and tissue samples—to identify biological markers that might one day predict who is at highest risk of developing substance use disorders.